The stock market today opened with steady cues, but one SME stock quickly grabbed attention. Accretion Nutraveda share price made its debut on the BSE SME platform on February 4, delivering a sharp premium over its IPO price and drawing strong interest from market participants tracking new listings.
The listing outcome reflects how SME issues continue to find space in the broader market narrative, especially when business models and issue structures resonate with investors.
Market Performance: Accretion Nutraveda Share Price on Listing Day
On its first day of trading, Accretion Nutraveda share price showed mixed but notable movements across platforms.
- Listed at ₹191 per share on BSE SME, a 48% premium over the IPO price of ₹129
- Listed on BSE at ₹155.60, which was 3.95% lower than the issue price
The variation between platforms highlighted early price discovery as the stock entered secondary market trading. Despite intraday fluctuations, the debut itself stood out in the stock market today due to the sizeable premium at listing.
Main News: Strong Debut After Fully Subscribed SME IPO
Accretion Nutraveda’s listing came after a successfully subscribed SME public issue that concluded in late January.
The IPO was open for subscription from January 28 to January 30, with the basis of allotment finalised on February 2. By the end of the bidding period, the issue was subscribed 1.83 times overall, indicating healthy participation across investor categories.
Subscription breakup showed:
- Retail investors: 2.19 times
- Non-institutional investors (NII): 2.08 times
- Qualified Institutional Buyers (QIBs): 1.01 times
In total, the company received bids for 23.44 lakh shares, compared with 12.80 lakh shares offered in the issue.
IPO Structure and Fundraising Details
The Accretion Nutraveda IPO was structured as a pure fresh issue, with no offer-for-sale component.
Key IPO details include:
- Issue size: ₹24.77 crore
- Fresh shares issued: 19 lakh
- Issue price: ₹129 per share
- Lot size: 2,000 shares
- Minimum retail investment: ₹2.58 lakh (two lots or 4,000 shares)
Before the public issue opened, the company had already raised ₹7 crore from anchor investors, providing early capital backing ahead of the main subscription window.
Use of IPO Proceeds
The company has outlined specific areas for deploying the funds raised through the public issue, with a clear focus on manufacturing and operational scale-up.
Planned utilisation includes:
- ₹4.22 crore for machinery to enhance automation at the existing manufacturing facility
- ₹8.03 crore for equipment procurement at a new manufacturing unit
- ₹5.50 crore towards working capital requirements
- Remaining funds for general corporate purposes
These allocations indicate a push toward capacity expansion and smoother day-to-day operations.
Company Details: Understanding Accretion Nutraveda
Founded in 2021, Accretion Nutraveda operates in the Ayurvedic and nutraceutical space. The company works as a Contract Development and Manufacturing Organization (CDMO), producing a wide range of health and wellness products.
Its manufacturing covers multiple dosage forms, including:
- Tablets and capsules
- Oral liquids and powders
- Oils and external applications such as balms, creams, and gels
The product portfolio blends traditional Ayurvedic formulations with modern nutraceutical science, targeting categories like:
- Liver care
- Women’s wellness
- Bone and joint health
- Cognitive and respiratory support
Beyond India, the company also caters to international markets such as Sri Lanka, Singapore, and the United States.
IPO Management and Market Infrastructure
The issue was managed and supported by established market intermediaries:
- Book-running lead manager: Sobhagya Capital Options Pvt. Ltd.
- Registrar: Kfin Technologies Ltd.
- Market maker: Sunflower Broking Pvt. Ltd.
These entities played a key role in executing the public issue and ensuring post-listing market operations.
Summary: What Accretion Nutraveda’s Listing Signals?
The debut of Accretion Nutraveda share price adds another data point to the SME market story playing out in the stock market today.
- The stock listed at a strong premium on BSE SME
- Subscription levels showed broad-based participation
- IPO proceeds are earmarked for manufacturing expansion and working capital
- The company operates in a niche segment combining Ayurveda and nutraceuticals
As SME listings continue to draw interest, Accretion Nutraveda’s market entry stands as a closely watched example of how younger companies transition from fundraising to public market trading—without fanfare, but with numbers that speak for themselves.
Source: Livemint
Easy & quick
Leave A Comment?